Tyra Biosciences, Inc. cash flow to debt ratio of -1.64K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Tyra Biosciences, Inc.'s free cash flow has decreased 35.27% from $-70.44M last year to $-95.28M, signaling decreasing performance

Tyra Biosciences, Inc.'s debt to equity ratio is 0.02, which means that the company's assets are healthy financed, signaling financial stability.

Tyra Biosciences, Inc.'s debt has increased relative to shareholder equity from 0.02 last year to 0.02 today, signaling weakened financials

Tyra Biosciences, Inc. has a net cash position, so leverage is healthy.

Tyra Biosciences, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Tyra Biosciences, Inc. has insufficient data to evaluate this check.

Tyra Biosciences, Inc.'s short-term assets of $265.45M exceed its short-term liabilities of $18.09M

Tyra Biosciences, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Tyra Biosciences, Inc.'s return on equity of -46.39%, is lower than 15.00%, indicating bad performance

Tyra Biosciences, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Tyra Biosciences, Inc. has insufficient public price history to evaluate earnings stability.

Tyra Biosciences, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Tyra Biosciences, Inc. has negative free cash flow, indicating cash burn

Tyra Biosciences, Inc.'s yearly earnings has decreased 38.70% since last year from $-86.48M to $-119.95M, signaling decreasing performance

Tyra Biosciences, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -44.78% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Tyra Biosciences, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Tyra Biosciences, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Tyra Biosciences, Inc. has insufficient public price history to evaluate ROE consistency.

Tyra Biosciences, Inc. has insufficient data to evaluate this check.

Tyra Biosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Tyra Biosciences, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Tyra Biosciences, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Tyra Biosciences, Inc. has insufficient data to evaluate this check.

Tyra Biosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Tyra Biosciences, Inc. has a price-to-book ratio of 4.90x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Tyra Biosciences, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue